Northwest Biotherapeutics, Inc.
NWBO
$0.214
$0.00170.80%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 357.00K | 510.00K | 284.00K | 445.00K | 406.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 357.00K | 510.00K | 284.00K | 445.00K | 406.00K |
| Cost of Revenue | 8.13M | 8.29M | 7.94M | 7.45M | 7.20M |
| Gross Profit | -7.77M | -7.78M | -7.66M | -7.01M | -6.80M |
| SG&A Expenses | 7.03M | 9.68M | 8.09M | 8.13M | 7.03M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.16M | 17.97M | 16.03M | 15.59M | 14.23M |
| Operating Income | -14.80M | -17.46M | -15.74M | -15.14M | -13.83M |
| Income Before Tax | -19.37M | -17.87M | -18.31M | -18.92M | -23.52M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.37M | -17.87M | -18.31M | -18.92M | -23.52M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.37M | -17.87M | -18.31M | -18.92M | -23.52M |
| EBIT | -14.80M | -17.46M | -15.74M | -15.14M | -13.83M |
| EBITDA | -14.36M | -17.03M | -15.32M | -14.72M | -13.41M |
| EPS Basic | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 1.26B | 1.21B | 1.19B | 1.16B | 1.13B |
| Average Diluted Shares Outstanding | 1.26B | 1.21B | 1.19B | 1.16B | 1.13B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
